Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes

References

• Frühbeck G, Toplak H, Woodward E, et al. Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013;6(2):117–120.
   PubMed Web of Science ®Google Scholar
• Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(Suppl 4):S164–92.
   PubMed Web of Science ®Google Scholar
• Global obesity observatory: interactive map [online]. [cited 2021 Nov 15]. Available from: https://data.worldobesity.org
   Google Scholar
• Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1–17.
   PubMed Web of Science ®Google Scholar
• Park JH, Yoon SJ, Lee H, et al. Burden of disease attributable to obesity and overweight in Korea. Int J Obes. 2006;30(11):1661–1669.
   PubMed Web of Science ®Google Scholar
• Avgerinos KI, Spyrou N, Mantzoros CS, et al. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metab Clin Exp. 2019;92:121–135.
   PubMed Web of Science ®Google Scholar
• Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–424.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 Suppl 3(Suppl 3):1–203.
   PubMedGoogle Scholar
• Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr. 2005;164(9):552–558.
   PubMed Web of Science ®Google Scholar
• Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol. 2004;58(2):119–133.
   PubMed Web of Science ®Google Scholar
• Mahmood I. Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact. 2009;24(1):57–81.
   PubMedGoogle Scholar
• McLeay SC, Morrish GA, Kirkpatrick CMJ, et al. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51(5):319–330.
   PubMed Web of Science ®Google Scholar
• Calvier EAM, Krekels EHJ, PAJ V, et al. Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade? Clin Pharmacokinet. 2017;56(3):273–285.
   PubMed Web of Science ®Google Scholar
• Eleveld DJ, Proost JH, Absalom AR, et al. Obesity and allometric scaling of pharmacokinetics. Clin Pharmacokinet. 2011;50(11):751–753.
   PubMed Web of Science ®Google Scholar
• van Rongen A, Krekels EH, Calvier EA, et al. An update on the use of allometric and other scaling methods to scale drug clearance in children: towards decision tables. Expert Opin Drug Metab Toxicol. 2022;18(2):99–113.
   PubMed Web of Science ®Google Scholar
• Dooley M, Singh S, Poole S, et al. Distribution and discordance of body surface area (BSA) and body mass index (BMI) in 4514 patients with malignancyutility of BMI to identify obese patients and its implications in BSA adjusted dosing of cytotoxics. InProc Am Soc Clin Oncol. 2002;21:356.
   Google Scholar
• Bauer LA, Edwards WA, Dellinger EP, et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643–647.
   PubMed Web of Science ®Google Scholar
• Duffull SB, Dooley MJ, Green B, et al. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet. 2004;43(15):1167–1178.
   PubMed Web of Science ®Google Scholar
• James WP Research on obesity. Group Report 1976.
   Google Scholar
• Green B, Duffull S. Caution when lean body weight is used as a size descriptor for obese subjects. Clin Pharmacol Ther. 2002;72(6):743–744.
   PubMed Web of Science ®Google Scholar
• Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–1065.
   PubMed Web of Science ®Google Scholar
• Pai MP, Nafziger AN, Bertino JS. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother. 2011;55(9):4006–4011.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Fukuda T, Knibbe CAJ, et al. Drug dosing in obese children: challenges and evidence-based strategies. Pediatr Clin North Am. 2017;64(6):1417–1438.
   PubMed Web of Science ®Google Scholar
• Smit C, de Hoogd S, Rjm B, et al. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 2018;14(3):275–285.
   PubMed Web of Science ®Google Scholar
• Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev. 1991;49(6):163–175.
   PubMed Web of Science ®Google Scholar
• Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage implications for drug therapy. Clin Pharmacokinet. 1994;26(4):292–307.
   PubMed Web of Science ®Google Scholar
• Han PY, Duffull SB, Kirkpatrick CMJ, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82(5):505–508.
   PubMed Web of Science ®Google Scholar
• Janmahasatian S, Duffull SB, Chagnac A, et al. Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol. 2008;65(6):964–965.
   PubMed Web of Science ®Google Scholar
• Ehmann L, Simon P, Busse D, et al. Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy. Clin Microbiol Infect. 2020;26(9):1222–1228.
   PubMed Web of Science ®Google Scholar
• Jittamala P, Pukrittayakamee S, Tarning J, et al. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. Antimicrob Agents Chemother. 2014;58(3):1615–1621.
   PubMed Web of Science ®Google Scholar
• Chairat K, Jittamala P, Hanpithakpong W, et al. Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. Br J Clin Pharmacol. 2016;81(6):1103–1112.
   PubMed Web of Science ®Google Scholar
• Ingrande J, Lemmens HJM. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 2010;105(Suppl 1):i16–23.
   PubMedGoogle Scholar
• James W. Research on obesity. Nutrition Bulletin. 1977;4(3):187–190
   Google Scholar
• Egan TD, Huizinga B, Gupta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology. 1998;89(3):562–573.
   PubMed Web of Science ®Google Scholar
• Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol. 2003;56(1):96–103.
   PubMed Web of Science ®Google Scholar
• van Rongen A, PAJ V, Peeters MYM, et al. Morbidly obese patients exhibit increased CYP2E1-mediated oxidation of Acetaminophen. Clin Pharmacokinet. 2016;55(7):833–847.
   PubMed Web of Science ®Google Scholar
• Rolle A, Paredes S, Cortínez LI, et al. Dexmedetomidine metabolic clearance is not affected by fat mass in obese patients. Br J Anaesth. 2018;120(5):969–977.
   PubMed Web of Science ®Google Scholar
• Bardin C, Nobecourt E, Larger E, et al. Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. Eur J Clin Pharmacol. 2012;68(6):961–968.
   PubMed Web of Science ®Google Scholar
• Diepstraten J, Janssen EJH, Hackeng CM, et al. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol. 2015;71(1):25–34.
   PubMed Web of Science ®Google Scholar
• Cortínez LI, Anderson BJ, Penna A, et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth. 2010;105(4):448–456.
   PubMed Web of Science ®Google Scholar
• Le J, Capparelli EV, Wahid U, et al. Bayesian Eetimation of vancomycin pharmacokinetics in obese children: matched case-control study. Clin Ther. 2015;37(6):1340–1351.
   PubMed Web of Science ®Google Scholar
• Wasmann RE, Heine ter R, van Dongen EP, et al. Pharmacokinetics of anidulafungin in obese and normal-weight adults. Antimicrob Agents Chemother. 2018;62:7.
   Web of Science ®Google Scholar
• Schmitt A, Gladieff L, Lansiaux A, et al. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res. 2009;15(10):3633–3639.
   PubMed Web of Science ®Google Scholar
• Nafziger AN, Bertino JS. Population pharmacokinetic analyses for ertapenem in subjects with a wide range of body sizes. Antimicrob Agents Chemother. 2018;62:10.
   Web of Science ®Google Scholar
• Smit C, Wasmann RE, Goulooze SC, et al. A prospective clinical study characterizing the influence of morbid obesity on the pharmacokinetics of gentamicin: towards individualized dosing in obese patients. Clin Pharmacokinet. 2019;58(10):1333–1343.
   PubMed Web of Science ®Google Scholar
• Wasmann RE, Smit C, Heine ter R, et al. Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. J Antimicrob Chemother. 2019;74(4):978–985.
   PubMed Web of Science ®Google Scholar
• Wasmann RE, Smit C, van Donselaar MH, et al. Implications for IV posaconazole dosing in the era of obesity. J Antimicrob Chemother. 2020;75(4):1006–1013.
   PubMed Web of Science ®Google Scholar
• van Kralingen S, Diepstraten J, Peeters MYM, et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet. 2011;50(11):739–750.
   PubMed Web of Science ®Google Scholar
• Smit C, Wasmann RE, Goulooze SC, et al. Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals. Br J Clin Pharmacol. 2020;86(2):303–317.
   PubMed Web of Science ®Google Scholar
• Pérus O, Marsot A, Ramain E. Performance of alfentanil target-controlled infusion in normal and morbidly obese female patients. Br J Anaesth. 2012;109(4):551–560.
   PubMed Web of Science ®Google Scholar
• Pai MP, Norenberg JP, Anderson T, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007;51(8):2741–2747.
   PubMed Web of Science ®Google Scholar
• Justo JA, Mayer SM, Pai MP, et al. Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects. Antimicrob Agents Chemother. 2015;59(7):3956–3965.
   PubMed Web of Science ®Google Scholar
• Smit C, van Schip AM, van Dongen EPA, et al. Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function. J Antimicrob Chemother. 2020;75(11):3286–3292.
   PubMed Web of Science ®Google Scholar
• Chung EK, Cheatham SC, Fleming MR, et al. Population pharmacokinetics and pharmacodynamics of meropenem in nonobese, obese, and morbidly obese patients. J Clin Pharmacol. 2017;57(3):356–368.
   PubMed Web of Science ®Google Scholar
• Thorne-Humphrey LM, Goralski KB, Slayter KL, et al. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). J Antimicrob Chemother. 2011;66(9):2083–2091.
   PubMed Web of Science ®Google Scholar
• Speed V, Green B, Roberts LN, et al. Fixed dose rivaroxaban can be used in extremes of bodyweight: a population pharmacokinetic analysis. J Thromb Haemost. 2020;18(9):2296–2307.
   PubMed Web of Science ®Google Scholar
• Smit C, Wasmann RE, Wiezer MJ, et al. Tobramycin clearance is best described by renal function estimates in obese and non-obese individuals: results of a prospective rich sampling pharmacokinetic study. Pharm Res. 2019;36(8):112.
   PubMed Web of Science ®Google Scholar
• Tsaousi G, Fyntanidou B, Stavrou G, et al. Propofol sedation for intragastric balloon removal: looking for the optimal body weight descriptor. Obes Surg. 2019;29(12):3882–3890.
   PubMed Web of Science ®Google Scholar
• Ingrande J, Brodsky JB, Lemmens HJM. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg. 2011;113(1):57–62.
   PubMed Web of Science ®Google Scholar
• Seth JS, Matok I, Kapur B. A comparison of folic acid pharmacokinetics in obese and nonobese women of childbearing age. Ther Drug Monit. 2011;33(3):336–340.
   PubMed Web of Science ®Google Scholar
• El-Baraky IA, Abbassi MM, Marei TA, et al. Obesity does not affect propofol pharmacokinetics during hypothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2016;30(4):876–883.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Wolff AC, Mathijssen RHJ, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007;25(30):4707–4713.
   PubMed Web of Science ®Google Scholar
• Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol. 2005;45(1):48–56.
   PubMed Web of Science ®Google Scholar
• Simon P, Petroff D, Busse D, et al. Meropenem plasma and interstitial soft tissue concentrations in obese and nonobese patients-a controlled clinical trial. Antibiotics (Basel). 2020;9(12):931.
   Web of Science ®Google Scholar
• de Hoogd S, Välitalo PAJ, Dahan A, Hoogd S de, Välitalo PAJ, Dahan A, et al. Influence of morbid obesity on the pharmacokinetics of morphine morphine-3-glucuronide, and morphine-6-glucuronide. Clin Pharmacokinet. 2017;56(12):1577–1587.
   PubMed Web of Science ®Google Scholar
• Pai MP. Pharmacokinetics of tedizolid in morbidly obese and covariate-matched nonobese adults. Antimicrob Agents Chemother. 2016;60(8):4585–4589.
   PubMed Web of Science ®Google Scholar
• Bunnell KL, Pai MP, Sikka M, et al. Pharmacokinetics of telavancin at fixed doses in normal-body-weight and obese (classes I, II, and III) adult subjects. Antimicrob Agents Chemother. 2018;62(4):4.
   Web of Science ®Google Scholar
• Butterfield-Cowper JM, Lodise TP, Pai MP. A fixed versus weight-based dosing strategy of daptomycin may improve safety in obese adults. Pharmacotherapy. 2018;38(9):981–985.
   PubMed Web of Science ®Google Scholar
• Sarich TC, Teng R, Peters GR, et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet. 2003;42(5):485–492.
   PubMed Web of Science ®Google Scholar
• Knibbe CAJ, Brill MJE, van Rongen A, et al. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55(1):149–167.
   PubMedGoogle Scholar
• Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90(1): 77–89.
   PubMed Web of Science ®Google Scholar
• Gillis PP, DeAngelis RJ, Wynn RL. Nonlinear pharmacokinetic model of intravenous anesthesia. J Pharm Sci. 1976;65(7):1001–1006.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Divoll M, et al. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). J Pharm Sci. 1982;71(8):942–944.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Divoll M, et al. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol. 1983;23(8–9):369–376.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther. 1987;42(2):193–200.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(1):27–35.
   PubMed Web of Science ®Google Scholar
• Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21(4):575–580.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. Clin Pharmacokinet. 1982;7(2):108–124.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ. Drug disposition in obese humans. An update. Clin Pharmacokinet. 1986;11(3):199–213.
   PubMed Web of Science ®Google Scholar
• Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999;88(1):1–7.
   PubMed Web of Science ®Google Scholar
• Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet. 1993;25(2):103–114.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Smith TW. Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J. 1981;102(4):740–744.
   PubMed Web of Science ®Google Scholar
• Christoff PB, Conti DR, Naylor C, et al. Procainamide disposition in obesity. Drug Intell Clin Pharm. 1983;17(7–8):516–522.
   PubMedGoogle Scholar
• Jaber LA, Antal EJ, Slaughter RL, et al. The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. Eur J Clin Pharmacol. 1993;45(5):459–463.
   PubMed Web of Science ®Google Scholar
• Brocks D, Al Nebaihi H, Parvin S, et al. Piecing together human adult comparative pharmacokinetic trials and rodent studies: what happens to drug clearance in obesity? J Pharm Pharm Sci. 2022;25:41–68.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Divoll M, et al. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet. 1984;9(2):177–183.
   PubMed Web of Science ®Google Scholar
• Flechner SM, Kolbeinsson ME, Tam J, et al. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation. 1989;47(5):806–810.
   PubMed Web of Science ®Google Scholar
• Cheymol G, Poirier JM, Barre J, et al. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol. 1987;27(11):874–879.
   PubMed Web of Science ®Google Scholar
• Cheymol G, Poirier JM, Carrupt PA, et al. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol. 1997;43(6):563–570.
   PubMed Web of Science ®Google Scholar
• Bowman SL, Hudson SA, Simpson G, et al. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol. 1986;21(5):529–532.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ. Lidocaine disposition in obesity. Am J Cardiol. 1984;53(8):1183–1186.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Divoll M, Greenblatt DJ, et al. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther. 1982;31(6):783–790.
   PubMed Web of Science ®Google Scholar
• Goday Arno A, Farré M, Rodríguez-Morató J, et al. Pharmacokinetics in morbid obesity: influence of two bariatric surgery techniques on paracetamol and caffeine metabolism. Obes Surg. 2017;27(12):3194–3201.
   PubMed Web of Science ®Google Scholar
• LA B, DJ B, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998;54(8):621–625.
   PubMed Web of Science ®Google Scholar
• Moretto M, Kupski C, Mottin CC, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obes Surg. 2003;13(4):622–624.
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–1119.
   PubMed Web of Science ®Google Scholar
• Brill MJE, Diepstraten J, van Rongen A, et al. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277–304.
   PubMed Web of Science ®Google Scholar
• Donato MT, Lahoz A, Jiménez N, et al. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos. 2006;34(9):1556–1562.
   PubMed Web of Science ®Google Scholar
• Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos. 2009;37(10):2087–2094.
   PubMed Web of Science ®Google Scholar
• Donato MT, Jiménez N, Serralta A, et al. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol In Vitro. 2007;21(2):271–276.
   PubMed Web of Science ®Google Scholar
• Woolsey SJ, Mansell SE, Kim RB, et al. CYP3A activity and expression in nonalcoholic fatty liver disease. Drug Metab Dispos. 2015;43(10):1484–1490.
   PubMed Web of Science ®Google Scholar
• Kolwankar D, Vuppalanchi R, Ethell B, et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol. 2007;5(3):388–393.
   PubMed Web of Science ®Google Scholar
• Ghose R, Omoluabi O, Gandhi A, et al. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci. 2011;89(1–2):57–64.
   PubMed Web of Science ®Google Scholar
• Zarezadeh M, Saedisomeolia A, Shekarabi M, et al. The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies. Eur J Nutr. 2021;60(6):2905–2921.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Morató J, Goday A, Langohr K, et al. Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity. Sci Rep. 2019;9(1):20405.
   PubMedGoogle Scholar
• Xu J, Kulkarni SR, Li L, et al. UDP-glucuronosyltransferase expression in mouse liver is increased in obesity- and fasting-induced steatosis. Drug Metab Dispos. 2012;40(2):259–266.
   PubMed Web of Science ®Google Scholar
• Caraco Y, Zylber-Katz E, Berry EM, et al. Carbamazepine Phakmacokinetics in obese and lean subjects. Ann Pharmacother. 1995;29(9):843–847.
   PubMed Web of Science ®Google Scholar
• van Wart S, Phillips L, Ludwig EA, et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 2004;48(12):4766–4777.
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Divoll M, et al. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and Acetaminophen. J Lab Clin Med. 1983;101(6):873–880.
   PubMed Web of Science ®Google Scholar
• Bentley JB. Obesity and alfentanil pharmacokinetics. Anesth Analg. 1983;62:251.
   Google Scholar
• Kvitne KE, Robertsen I, Skovlund E, et al. Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A-activity - a non-randomized three-armed controlled trial. Clin Transl Sci. 2021;15(1):221–233.
   PubMed Web of Science ®Google Scholar
• Brill MJE, van Rongen A, Houwink API, et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. Clin Pharmacokinet. 2014;53(10):931–941.
   PubMed Web of Science ®Google Scholar
• Caraco Y, Zylber-Katz E, Berry EM, et al. Significant weight reduction in obese subjects enhances carbamazepine elimination. Clin Pharmacol Ther. 1992;51(5):501–506.
   PubMed Web of Science ®Google Scholar
• Li XS, Nielsen J, Cirincione B, et al. Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist. AAPS J. 2010;12(4):537–547.
   PubMed Web of Science ®Google Scholar
• Chew DJ, DiBartola SP, Schenck PA, editors. Canine and feline nephrology and urology. Saunders: Elsevier Health Sciences; 2010.
   Google Scholar
• Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757–773.
   PubMed Web of Science ®Google Scholar
• Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988;84(6):1053–1060.
   PubMed Web of Science ®Google Scholar
• Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010;17(5):e53–62.
   PubMedGoogle Scholar
• Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308–318.
   PubMed Web of Science ®Google Scholar
• Dorn C, Petroff D, Neumann N, et al. Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial. J Antimicrob Chemother. 2019;74(8):2335–2340.
   PubMed Web of Science ®Google Scholar
• Alobaid AS, Wallis SC, Jarrett P, et al. Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients. Antimicrob Agents Chemother. 2016;60(11):6550–6557.
   PubMed Web of Science ®Google Scholar
• Dorn C, Petroff D, Kees MG, et al. Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. J Antimicrob Chemother. 2021;76(8):2114–2120.
   PubMed Web of Science ®Google Scholar
• Brill MJE, Houwink API, Schmidt S, et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother. 2014;69(3):715–723.
   PubMed Web of Science ®Google Scholar
• Cortínez LI, Anderson BJ, Holford NHG, et al. Dexmedetomidine pharmacokinetics in the obese. Eur J Clin Pharmacol. 2015;71(12):1501–1508.
   PubMed Web of Science ®Google Scholar
• Shukla UA, Chi EM, Lehr K-H. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacother. 2004;38(1):30–35.
   PubMed Web of Science ®Google Scholar
• Addy C, Tatosian DA, Glasgow XS, et al. Effects of age, sex, and obesity on the single-dose pharmacokinetics of omarigliptin in healthy subjects. Clin Pharmacol Drug Dev. 2016;5(5):374–382.
   PubMed Web of Science ®Google Scholar
• Dong D, Peng X, Liu J, et al. Morbid obesity alters both pharmacokinetics and pharmacodynamics of propofol: dosing recommendation for anesthesia induction. Drug Metab Dispos. 2016;44(10):1579–1583.
   PubMed Web of Science ®Google Scholar
• Milsap R L, Plaisance K I and Jusko W J. (1984). Prednisolone disposition in obese men. Clin Pharmacol Ther, 36(6), 824–831. DOI: 10.1038/clpt.1984.263
   PubMed Web of Science ®Google Scholar
• Dunn T E, Ludwig E A, Slaughter R L, Camara D S and Jusko W J. (1991). Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther, 49(5), 536–549. DOI: 10.1038/clpt.1991.64
   PubMed Web of Science ®Google Scholar
• Xu B, Zhou D, Ren L, et al. Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. J Anesth. 2017;31(6):813–820.
   PubMed Web of Science ®Google Scholar
• Pai MP, Cojutti P, Pea F. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections. Clin Pharmacokinet. 2015;54(9):933–941.
   PubMed Web of Science ®Google Scholar
• Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. A preliminary study. Eur J Clin Pharmacol. 2000;56(4):293–297.
   PubMed Web of Science ®Google Scholar
• Joseph PD, Craig JC, Caldwell PHY. Clinical trials in children. Br J Clin Pharmacol. 2015;79(3):357–369.
   PubMed Web of Science ®Google Scholar
• Kendrick JG, Carr RR, Ensom MHH. Pharmacokinetics and drug dosing in obese children. J Pediatr Pharmacol Ther. 2010;15(2):94–109.
   PubMedGoogle Scholar
• Mulla H, Johnson TN. Dosing dilemmas in obese children. Arch Dis Child Educ Pract Ed. 2010;95(4):112–117.
   PubMed Web of Science ®Google Scholar
• Kendrick JG, Carr RR, Ensom MHH. Pediatric obesity: pharmacokinetics and implications for drug dosing. Clin Ther. 2015;37(9):1897–1923.
   PubMed Web of Science ®Google Scholar
• Ross EL, Heizer J, Mixon MA, et al. Development of recommendations for dosing of commonly prescribed medications in critically ill obese children. Am J Health Syst Pharm. 2015;72(7):542–556.
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Boelens JJ, Bredius RGM, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51(5):331–345.
   PubMed Web of Science ®Google Scholar
• Bartelink IH, van Kesteren C, Boelens JJ, et al. Predictive performance of a busulfan pharmacokinetic model in children and young adults. Ther Drug Monit. 2012;34(5):574–583.
   PubMed Web of Science ®Google Scholar
• Diepstraten J, Chidambaran V, Sadhasivam S, et al. An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst Pharmacol. 2013;2(9):e73.
   PubMedGoogle Scholar
• Schüttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology. 2000;92(3):3.
   PubMed Web of Science ®Google Scholar
• van Rongen A, Brill MJE, Vaughns JD, et al. Higher midazolam clearance in obese adolescents compared with morbidly obese adults. Clin Pharmacokinet. 2018;57(5):601–611.
   PubMed Web of Science ®Google Scholar
• van Rongen A, van der Aa MP, Matic M, et al. Increased metformin clearance in overweight and obese adolescents: a pharmacokinetic substudy of a randomized controlled trial. Paediatr Drugs. 2018;20(4):365–374.
   PubMed Web of Science ®Google Scholar
• Vaughns JD, Ziesenitz VC, Williams EF, et al. Use of fentanyl in adolescents with clinically severe obesity undergoing bariatric surgery: a pilot study. Paediatr Drugs. 2017;19(3):251–257.
   PubMed Web of Science ®Google Scholar
• Calvier EAM, Krekels EHJ, Yu H, et al. Drugs being eliminated via the same pathway will not always require similar pediatric dose adjustments. CPT Pharmacometrics Syst Pharmacol. 2018;7(3):175–185.
   PubMedGoogle Scholar